26 results about "Endometriosis" patented technology

The invention discloses a full-cycle management method for an endometriosis patient, and relates to the technical field of medical informatization decision making, and the method comprises the steps: collecting the preliminary diagnosis disease staging information, lesion feature text and laboratory inspection data of the patient, and generating a case data set through medical term standardized conversion and text structured processing; constructing a recurrence risk prediction model, inputting the case data set into the recurrence risk prediction model, and generating a recurrence risk quantitative score; adjusting a follow-up period based on the recurrence risk quantitative score, setting follow-up time nodes and medical examination items, and combining to generate a follow-up plan; and performing graded reminding based on the follow-up visit plan, and collecting symptom scoring records, medicine use data and life quality evaluation results submitted by the patient to form a follow-up visit data set. The dynamic follow-up visit plan is generated by constructing the recurrence risk prediction model, individualized follow-up visit management is achieved, and the problem that follow-up visit depends on static experience and cannot be matched with a real risk level is solved.

The present disclosure relates to diagnostic and therapeutic applications of photobiomodulation and light therapies such as red-light therapy and electrical stimulation devices. Application areas include gut, uterine and other pelvic conditions, back pain, endometriosis, fibromyalgia, etc. The methods and devices disclosed herein are used for delivering targeted therapy using personalized and adjustable treatment protocols which may use features such as real-time monitoring and closed-loop feedback. The devices described herein can be worn discretely to deliver therapy. The present disclosure also includes artificial intelligence and machine learning-based methods for such diagnostic and therapeutic applications.

Methods for diagnosing or monitoring endometriosis in a mammal are provided. The methods include the steps of determining the expression levels of BDNF, glycodelin and optionally ZAG, in a biological sample from the mammal, and determining that the mammal has endometriosis when the biomarker expression levels in the sample are elevated.

The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and / or dysmenorrhea comprising administering drospirenone in a biphasic regimen. The present invention further relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to pharmaceutical compositions and kits comprising drospirenone administered in such a biphasic regimen.

The present invention relates to injectable microspheres and formulations comprising the microspheres for controlled release of progestogen hormones. The present invention also relates to a method of preparing the microspheres that control the release of the progestogen hormone and methods of using the microspheres that control the release of the progestogen hormone to treat conditions such as pregnancy and fertility in women as well as gynecological disorders such as secondary amenorrhea, endometriosis, abnormal uterine bleeding due to hormonal imbalance, and acne.

In order to prepare the medicine for effectively inhibiting the endometriosis, the invention provides the application of the interleukin 17C blocking agent in preparing the medicine for inhibiting the endometriosis, the interleukin 17C blocking agent is MOR106 and / or a monoclonal antibody which has 90% sequence identity with the MOR106, and the monoclonal antibody has an antigenic determinant corresponding to the interleukin 17C.

This disclosure belongs to the field of pharmaceutical technology, and specifically relates to the application of targeted proline metabolic enzymes in the treatment of endometriosis. This disclosure, through in vitro experiments and EMS animal models, verifies that the proline content in ectopic endometrial stromal cells increases, the expression of proline synthesis metabolic enzymes is elevated, and fibrosis is significantly activated. This disclosure creatively repurposes proline metabolic enzyme inhibitors for EMS treatment. Proline metabolic enzyme inhibitors specifically inhibit the enzyme activity of key proline metabolism enzymes, blocking the synthesis pathway from glutamate to proline, and directly reducing intracellular proline content. Since proline is a major component amino acid of collagen, the inhibition of proline synthesis directly inhibits collagen synthesis and the expression of fibrosis markers in endometrial stromal cells, ultimately achieving the therapeutic effect of inhibiting fibrosis in EMS ectopic lesions and reducing ectopic lesion growth.

The invention belongs to the technical field of biological medicine, and discloses application of DON in relieving ovarian fibrosis. The invention discloses an application of DON or a pharmaceutically acceptable derivative thereof in preparation of a medicine for treating or preventing ovarian fibrosis. The invention discloses application of DON in prevention and treatment of ovarian fibrosis, human ovarian is cultured in vitro, DON is added for treatment, and the result shows that DON can reduce the ovarian fibrosis level, so that DON can be used as a potential medicine for recovering female fertility. The DON is prompted to have an obvious promoting effect on recovery of ovarian fibrosis, so that the DON can be used for solving the problems of ovarian fibrosis, non-ovulation and the like caused by endometriosis, and a new medicine choice is provided for clinical treatment of infertility.

The present disclosure relates to a chemogenetic system and method treating endometriosis using a gene therapy vector to deliver a therapeutic payload to specific cells (nociceptive neurons). Overexpression of the payload increases the sensitivity of the cells to an activator, thereby enabling lower doses of activator drugs to be administered. The disclosure also related to vectors to deliver a nucleotide sequence to the target cells to enable overexpression thereof.

In order to prepare a medicine for effectively inhibiting endometriosis, the application provides an application of interleukin 17C blocking agent in preparation of a medicine for inhibiting endometriosis, wherein the interleukin 17C blocking agent is MOR106 and / or a monoclonal antibody with 90% sequence identity with MOR106, and the monoclonal antibody has an antigenic determinant corresponding to interleukin 17C.

The present disclosure relates to a chemogenetic system and method treating endometriosis using a gene therapy vector to deliver a therapeutic payload to specific cells (nociceptive neurons). Overexpression of the payload increases the sensitivity of the cells to an activator, thereby enabling lower doses of activator drugs to be administered. The disclosure also related to vectors to deliver a nucleotide sequence to the target cells to enable overexpression thereof.

The application discloses a kind of endometriosis patient lactation review follow-up data processing system, it is related to medical data processing technical field, the system passes through acquisition patient hospital information, follow-up record, self-report data and equipment monitoring data, and using BERT medical NLP model is carried out vectorization processing to text illness record, standardization storage is realized in combination with NER, and patient data set is arranged according to time sequence;Abnormal data is scored using local anomaly factor and isolation forest algorithm, and provides abnormal data processing strategy;Based on time series analysis and EWMA method, calculate trend change coefficient BQS, monitor the trend of illness change and early warning;Through Euclidean distance, cosine similarity and clustering algorithm analysis patient illness trajectory, calculate similarity score Sxs, judge illness similarity, and provide corresponding strategy to high similarity patient.

The invention concerns the treatment of endometriosis using an anti-netrin- 1 antibody or an antigen-binding fragment thereof, and such antibody or fragment thereof for use in treating endometriosis. Said treating comprises a reduction of the endometriosis lesions, especially the uterine and / or uterine horn endometriosis lesions. Said treating further comprises a chronic pelvic pain relief or vaginal hyperalgesia relief. It may also comprise a reduction of colorectal hyperalgesia developed in endometriosis, an improvement of bladder dysfunction developed in endometriosis, a reduction of enhanced cutaneous sensitivity to thermal and / or mechanical stimuli developed in endometriosis, an improvement of the overall wellbeing altered by the endometriosis.

The invention relates to the technical field of biomedical treatment, in particular to combined lactobacillus salivarius and application of the combined lactobacillus salivarius in preparation of medicines for treating EMT. The combined lactobacillus salivarius NCU-03 has probiotic properties, can reduce the production of endometriosis focus blood vessels and the proliferation of cells by inhibiting the expression of VEGF and PCNA, and can reduce the expression levels of IL-6, IL-1beta and TNF-alpha to inhibit the development of endometriosis. Therefore, the combined lactobacillus salivarius NCU-03 can be used for treating the endometriosis.

The present invention provides a composition, in particular, a pharmaceutical composition and a food and drink composition, for preventing or treating endometriosis, the composition containing polyphosphoric acid or a salt thereof. The salt of the polyphosphoric acid may be a metal salt of polyphosphoric acid, may contain, as a constituent metal thereof, at least one among sodium, potassium, magnesium, calcium, and zinc, and is preferably calcium polyphosphate or zinc polyphosphate. According to the present invention, the prevention or treatment of endometriosis based on a novel action mechanism, which is highly safe to a living body, is possible.

The present application relates to the field of biological medical technology, and in particular to Bifidobacterium longum subsp. longum and its application in drugs related to reproductive system diseases. Bifidobacterium longum subsp. longum The present application provides a Bifidobacterium longum subsp. longum (NCU-06) strain, which has been preserved in the China General Microbiological Culture Collection Center, located at No. 1, Yihuangyuan 3rd, Beichen West Road, Chaoyang District, Beijing, on January 18, 2023, and the preservation number is CGMCC No. 26491. The above-mentioned Bifidobacterium longum subsp. longum NCU-06 has a therapeutic effect on various female reproductive system diseases, for example, it can be used to treat endometriosis, ovarian cancer, paraneoplastic thrombocytosis of ovarian cancer, and ovarian hyperstimulation syndrome.

The application relates to an endometriosis organoid intelligent monitoring method, system, device and medium method and system. The method comprises the following steps: acquiring bright field images of an experimental culture cavity and a reference culture cavity in a microfluidic double-chamber, acquiring temperature sensing data and pH sensing data of the two chambers; inputting a lightweight convolutional neural network for foreground segmentation to obtain organoid segmentation masks of the two chambers; extracting morphological features based on the segmentation masks to identify invasive phenotypes, and obtaining invasive indexes and invasive phenotype labels of the two chambers; combining the segmentation masks and the pH sensing data to calculate a target perfusion rate; driving a microfluidic perfusion system to regulate the flow rate, performing temperature proportional integral differential control according to the temperature sensing data to generate temperature regulation state data; and integrating the above data to generate an endometriosis organoid intelligent monitoring result. The method can realize intelligent monitoring and closed-loop regulation of the culture environment of endometriosis organoids, and improve the accuracy and experimental efficiency of organoid invasiveness evaluation.

The invention relates to an application of a miR-15b-5p expression quantity detection agent in preparation of an endometriosis diagnostic agent, and an endometriosis diagnostic kit. According to the invention, the expression quantity of miR-15b-5p in a serum exosome is used as a diagnostic marker of endometriosis, the sensitivity is 0.908, the specificity is 0.881, the false positive rate is 0.119, the false negative rate is 0.092, and the AUC value of an ROC curve is 0.898. Therefore, the sensitivity and the specificity of the miR-15b-5p are very high, and the miR-15b-5p has a relatively good diagnostic value.

A method for treating a noncancerous gynecological disorder comprising: administering to a patient an effective amount of composition to a patient, the composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.

This invention provides a triptolide sustained-release hydrogel targeting the FOSB and TGFB1 axes and its applications, belonging to the field of biomedical materials and drug delivery technology. The sustained-release hydrogel is a core-shell structured sequential release hydrogel. The outer layer is a 40 mg / mL low-concentration gelatin methacrylamide hydrogel loaded with stromal cell-derived factor-1α (SDF-1α), and the inner layer is a 60 mg / mL high-concentration GelMA hydrogel loaded with triptolide. This invention is the first to clearly demonstrate that the transcription factor FOSB constitutes a core driving pathway for endometriosis fibrosis by transcribing and activating TGFB1. Triptolide can directly bind to FOSB and promote its ubiquitination-mediated degradation, thereby blocking the TGF-β / Smad signaling pathway and mesenchymal-myofibroblast transformation. Through a synergistic recruitment-targeted inhibition strategy using core-shell hydrogels, SDF-1α rapidly recruits myofibroblasts in the lesion area, and tripterygium wilfordii achieves local sustained release over 14 days. While significantly inhibiting fibrosis and reducing the size of endometriosis lesions, it avoids the hepatotoxicity and off-target damage of free drugs.

The present disclosure relates to compounds which inhibit one or more members of the neurotrophic receptor tyrosine kinase (NTRK) family (i.e., NTRK1, NTRK2, and / or NTRK3), and pharmaceutical compositions thereof. In another aspect, the present disclosure provides a method of treating, preventing, and / or ameliorating at least one disease and / or disorder selected from the group consisting of endometriosis, cancer, and pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure and / or a pharmaceutical composition of the present disclosure.

Methods of treating endometriosis through modulation of Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) activity including administration of an NR4A1 ligand to an individual in need thereof are described. In an embodiment, the compounds include methylene substituted diindolylmethanes.

The present application relates to a kind of gonadotropin releasing hormone antagonists, it has the antagonistic activity to gonadotropin releasing hormone, and can be used to prevent or treat sex hormone-dependent diseases, such as benign prostatic hypertrophy, uterine fibroids, endometriosis, uterine fibroids, precocious puberty, amenorrhea, premenstrual syndrome, dysmenorrhea and the like, or its prodrug, or its pharmaceutically acceptable salt, or its hydrate or solvate, and the pharmaceutical composition containing it.

The invention relates to application of a combined miRNA expression quantity detection agent in preparation of an endometriosis diagnostic agent and an endometriosis diagnostic kit. The expression quantity of the combined miRNA in the serum exosome is used as a diagnostic marker of endometriosis, the sensitivity is 0.846, the specificity is 0.898, the false positive rate is 0.102, and the ROC curve AUC value is 0.921. Therefore, both the sensitivity and the specificity of the combined miRNA are very high, and the combined miRNA has a relatively good diagnostic value.

Disclosed herein are compositions comprising an Interleukin-33 (IL-33) inhibitor, an Interleukin-1 receptor-like 1 (ST2) receptor inhibitor or a combination thereof, and methods for treating endometriosis.